Pharma company Wanbury launches Nitrofur SR

Pharma company, Wanbury, today said it has launched its New Drug Delivery System (NDDS) product, Nitrofur SR (Nitrofurantoin-100 mg), targeted at Urinary Tract Infections (UTI) for the first time in the country.     

The molecule Nitrofurantoin is highly effective in the treatment of urinary tract infection.      

"Wanbury's Nitrofur SR, due to its unique hydrophilic polymer matrix or HPM technology, makes it a once-a-day, sustained release product. It is highly-effective compared to instant release formulations and is without any side-effects," Wanbury's Director (Marketing and Sales), Rajaram Samant, said in a press release issued here.     

According to industry estimates, the size of the UTI market in the country is about Rs 1,200 crore, and growing annually at 14 per cent.     

 

It is alarming that in the country over 28 per cent of women visiting gynecologists suffer from UTI.     

"We will be targeting this 28 per cent population. We plan Nitrofur SR sales of Rs 10 crore in the first year of the launch and hope to capture a substantial share of the UTI market in the next three years," he said.     

Wanbury would be marketing the product with leading gynecologists and urologists in the country.     

Wanbury is the third company in India to have entered the unexplored market of Nitrofurantoin.